Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06DWA
|
|||
| Former ID |
DNC009029
|
|||
| Drug Name |
(Sar)WTLNSAGYLLGPKK(Lys-MPEG4)K
|
|||
| Synonyms |
CHEMBL505299; (Sar)WTLNSAGYLLGPKK(Lys-MPEG4)K
Click to Show/Hide
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C99H163N23O28
|
|||
| Canonical SMILES |
CC(C)CC(C(=O)NC(CC(C)C)C(=O)NCC(=O)N1CCCC1C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCNC(=O)COCCOCCOCCOCCOC)C(=O)NC(CCCCN)C(=O)N)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)CNC(=O)C(C)NC(=O)C(CO)NC(=O)C(CC(=O)N)NC(=O)C(CC(C)C)NC(=O)C(C(C)O)NC(=O)C(CC3=CNC4=CC=CC=C43)OC(=O)CNC
|
|||
| InChI |
1S/C99H163N23O28/c1-58(2)46-72(88(133)109-54-83(129)122-37-21-28-78(122)97(142)115-71(26-15-19-35-102)91(136)113-69(25-14-18-34-101)90(135)114-70(89(134)112-68(86(104)131)24-13-17-33-100)27-16-20-36-106-82(128)57-149-45-44-148-43-42-147-41-40-146-39-38-145-10)116-92(137)73(47-59(3)4)117-94(139)75(49-63-29-31-65(125)32-30-63)111-81(127)53-108-87(132)61(7)110-96(141)77(56-123)120-95(140)76(51-80(103)126)118-93(138)74(48-60(5)6)119-99(144)85(62(8)124)121-98(143)79(150-84(130)55-105-9)50-64-52-107-67-23-12-11-22-66(64)67/h11-12,22-23,29-32,52,58-62,68-79,85,105,107,123-125H,13-21,24-28,33-51,53-57,100-102H2,1-10H3,(H2,103,126)(H2,104,131)(H,106,128)(H,108,132)(H,109,133)(H,110,141)(H,111,127)(H,112,134)(H,113,136)(H,114,135)(H,115,142)(H,116,137)(H,117,139)(H,118,138)(H,119,144)(H,120,140)(H,121,143)/t61-,62+,68-,69-,70-,71-,72-,73-,74-,75-,76-,77-,78-,79-,85-/m0/s1
|
|||
| InChIKey |
MJZZQPFMLULOPB-UJNSRDRFSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Galanin receptor type 1 (GAL1-R) | Target Info | Inhibitor | [1] |
| Galanin receptor type 2 (GAL2-R) | Target Info | Inhibitor | [1] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Reactome | Peptide ligand-binding receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Peptide GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Structural requirements for a lipoamino acid in modulating the anticonvulsant activities of systemically active galanin analogues. J Med Chem. 2009 Mar 12;52(5):1310-6. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.